OLEMA PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $218.00K, a 6.84% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $4.02M, a 1604.66% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $7.68M, a 1781.62% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $7.00K, a 92.63% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $8.15M, a 437.15% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.52M, a 44.23% decline from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $2.72M, a 1764.38% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $146.00K, a 78.21% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $218.00K 10-Q · filed 2026-08-10 | $11.93M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $4.02M 10-Q · filed 2026-05-12 | $11.94M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $7.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.15M 10-K · filed 2026-03-16 |
| 2025-09-30 | $7.00K 10-Q · filed 2025-11-10 | $885.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $234.00K 10-Q · filed 2026-08-10 | $973.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $236.00K 10-Q · filed 2026-05-12 | $814.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $408.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.52M 10-K · filed 2026-03-16 |
| 2024-09-30 | $95.00K 10-Q · filed 2025-11-10 | $1.39M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $75.00K 10-Q · filed 2025-08-11 | $2.19M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $940.00K 10-Q · filed 2025-05-13 | $3.44M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $2.72M 10-K · filed 2025-03-18 |
| 2023-09-30 | $891.00K 10-Q · filed 2024-11-12 | $2.44M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.33M 10-Q · filed 2024-08-06 | $1.66M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $220.00K 10-Q · filed 2024-05-08 | $333.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $146.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | $106.00K 10-Q · filed 2023-11-07 | $629.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $7.00K 10-Q · filed 2023-08-08 | $580.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $33.00K 10-Q · filed 2023-05-09 | $703.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $483.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $670.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $57.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $130.00K 10-Q · filed 2022-08-09 | |
| 2020-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $151.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $120.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |